Blog& Insights_Hangzhou Healsun Biopharm Co.,Ltd.

新(xīn)聞

最新(xīn)資訊

傳遞熱點，提升價值

Comparative Analysis of N-1 Perfusion Strategies for Enhanced Protein Expression and Cost Efficiency in Biopharmaceutical Manufacturing

2024 / 06 / 21 了解詳情 >>
Method Validation: Elevate your shooting precision in the course of Process Development

2023 / 08 / 31 了解詳情 >>
Construction of CHO Cell Lines Expressing Antibodies with Low Fucose Level by Gene Editing Technolog

2023 / 08 / 17 了解詳情 >>
Antibody Disulfide Bonds and ADCs

2023 / 08 / 09 了解詳情 >>
Read the Coffee Grounds -- Stability Study During Cell Line Construction

2023 / 07 / 26 了解詳情 >>
Get ahead in the race for CMC development success - Accelerating CMC development for bispecific anti

2023 / 07 / 06 了解詳情 >>
Feeding Development-Sphinx Riddle

2023 / 08 / 24 了解詳情 >>
資訊 | 揚帆浩瀚，陟遐自迩——開啓新(xīn)篇章

2023 / 05 / 04 了解詳情 >>
資訊 I 皓陽生物(wù)獲評“2022年度浙江省第二批專精(jīng)特新(xīn)中小(xiǎo)企業名單”

2023 / 02 / 01 了解詳情 >>

<
1
2
>

Email：healsunbd@hs-biopharm.com

Early-Stage
Biologics ADC Protein Store
CMC Process
Cell Line Development Biologics Process Development ADC Process Development Analytical Support
GMP Pilot Production
Biologics ADC
Commercial Production
PC/PV Commercial Production
CGT
Exosome mRNA AAV
Biosimilars
Biosimilars
About Us
Company Profile VR Tour Contact Us

Copyright © 2023 杭州皓陽生物(wù)技(jì )術有限公司All Rights Reserved 京ICP證000000号浙公網安(ān)備 33011002011493号技(jì )術支持：杭州網站制作(zuò)